• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4832873)   Today's Articles (5695)
For: Mizoshita T, Tanida S, Tsukamoto H, Ozeki K, Katano T, Nishiwaki H, Ebi M, Mori Y, Kubota E, Kataoka H, Kamiya T, Joh T. Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement. Gastroenterol Res Pract 2014;2014:687257. [PMID: 24829572 DOI: 10.1155/2014/687257] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/13/2014] [Revised: 03/22/2014] [Accepted: 03/24/2014] [Indexed: 01/23/2023]  Open
Number Cited by Other Article(s)
1
Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease. Dig Liver Dis 2019;51:967-971. [PMID: 30872086 DOI: 10.1016/j.dld.2018.10.024] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2018] [Revised: 10/09/2018] [Accepted: 10/11/2018] [Indexed: 12/11/2022]
2
Suzuki T, Mizoshita T, Sugiyama T, Hirata Y, Kimura Y, Suzuki Y, Yamada T, Tsukamoto H, Mizushima T, Sugimura N, Katano T, Tanida S, Kataoka H, Sasaki M. Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment. Case Rep Gastroenterol 2019;13:37-49. [PMID: 31182942 PMCID: PMC6547276 DOI: 10.1159/000496453] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/15/2018] [Accepted: 12/19/2018] [Indexed: 01/07/2023]  Open
3
Mizoshita T, Tanida S, Ozeki K, Katano T, Shimura T, Mori Y, Kubota E, Kataoka H, Kamiya T, Joh T. Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab. Case Rep Gastroenterol 2016;10:283-91. [PMID: 27462198 PMCID: PMC4939671 DOI: 10.1159/000445105] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2016] [Accepted: 02/29/2016] [Indexed: 01/26/2023]  Open
4
Mizoshita T, Tanida S, Joh T. Adalimumab treatment in intestinal Behçet's disease: Relationship with ectopic mucin 5AC glycoprotein expression and endoscopic improvement. Dig Liver Dis 2015;47:991-2. [PMID: 26250949 DOI: 10.1016/j.dld.2015.07.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2015] [Revised: 06/18/2015] [Accepted: 07/09/2015] [Indexed: 12/11/2022]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA